After Today’s Bearish Options Activity, Is Shire PLC (ADR)’s Near-Term Analysis Positive?

 After Today's Bearish Options Activity, Is Shire PLC (ADR)'s Near Term Analysis Positive?

In today’s session Shire PLC (ADR) (SHPG) recorded an unusually high (1,184) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious SHPG decrease. With 1,184 contracts traded and 23504 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: SHPG161118P00170000 closed last at: $3.4 or 12.8% down. About 1.57M shares traded hands or 31.93% up from the average. Shire PLC (ADR) (NASDAQ:SHPG) has risen 2.86% since March 29, 2016 and is uptrending. It has underperformed by 0.61% the S&P500.

Shire PLC (ADR) (NASDAQ:SHPG) Ratings Coverage

Out of 18 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 15 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 83% are positive. $325 is the highest target while $210 is the lowest. The $254.89 average target is 51.62% above today’s ($168.11) stock price. Shire plc (ADR) has been the topic of 28 analyst reports since July 22, 2015 according to StockzIntelligence Inc. As per Friday, May 6, the company rating was initiated by Liberum Capital. Credit Suisse upgraded the stock to “Outperform” rating in Tuesday, January 12 report. As per Tuesday, November 17, the company rating was upgraded by Leerink Swann. On Tuesday, November 3 the stock rating was upgraded by HSBC to “Buy”. On Tuesday, October 27 the stock rating was upgraded by HSBC to “Buy”. The firm has “Overweight” rating by Morgan Stanley given on Friday, June 3. The company was maintained on Friday, June 3 by Jefferies. The stock has “Sector Perform” rating given by RBC Capital Markets on Monday, October 26. The stock has “Buy” rating given by Bryan Garnier & Cie on Monday, May 23. RBC Capital Markets maintained the stock with “Sector Perform” rating in Tuesday, January 12 report.

According to Zacks Investment Research, “Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)”

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of $49.00 billion. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 26.7 P/E ratio.

SHPG Company Profile

Shire plc, incorporated on January 28, 2008, is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.

More recent Shire PLC (ADR) (NASDAQ:SHPG) news were published by: Businessfinancenews.com which released: “Shire PLC (ADR) Future Now Rests On Xiidra” on July 12, 2016. Also Businessfinancenews.com published the news titled: “Shire Goes Deeper into Hemophilia Segment” on August 01, 2016. Businessfinancenews.com‘s news article titled: “Will Shire PLC (ADR) be the Market Leader in ADHD?” with publication date: April 06, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment